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Role of Connective Tissue Proteases
in the Pathogenesis of Chronic
Inflammatory Lung Disease
by James E. Gadek,*t Gerald A. Fells,*
Raymond L. Zimmerman* and Ronald G. Crystal*
The normal structure and function ofthe human lung is dependent on the maintenance ofthe connective
tissue matrix. These structural macromolecules provide the template for normal parenchymal cell
architecture on which efficient gas exchange depends. In addition, the organization and amount of this
extracellular matrix accounts for much of the mechanical behavior of the lung parenchyma during the
respiratory cycle. The preservation of this intricate connective tissue scaffold depends on the lung's
capacity to prevent enzymatic disruption of the component matrix proteins. Specifically, the integrity of
the normal connective tissue skeleton ofthe lung is determined by the maintenance of a balance between
proteases capable of cleaving these structural elements and the specific protease inhibitors. The normal
extracellular matrix is preserved when the local concentrations ofprotease inhibitors prohibits expression
of active connective tissue proteases within the lung parenchyma. Conversely, the disruption of lung
structure during the course ofacute and chronic inflammatory diseases ofthe lung is often associated with
an imbalance ofprotease-antiprotease activity. The consequence istheexpression ofunimpeded proteolytic
attack on the connective tissue matrix ofthe lung. In this context, the nature ofthe pulmonary lesion and
its physiologic consequences, reflect the specificity ofthe expressed proteases for the individual connective
tissue components. Experimental evidence suggests that the differential expression of collagenase and
elastase, prototypes of connective tissue proteases, may determine whether the pathologic outcome is
fibrosis (e.g., idiopathic pulmonary fibrosis) or destruction (e.g., emphysema) of the alveolar structures.
The structure and function of the normal lung are
intimately dependent on the integrity ofthe connective
tissue elements comprising the alveolar structures (1).
These macromolecules provide the scaffolding that
permits the normal cellular architecture necessary for
effective gas exchange and account for the normal
mechanical behavior ofthe lung during the respiratory
cycle.
One of the most devastating consequences of inflam-
mation in the lung results from the action of cellular
enzymes that cleave the polypeptide backbone of the
connective tissue proteins within the alveolar structures
(2,3). When the local concentration of these connective
tissue proteases exceeds the capacity of the lung to
check their activity, the resultant disruption of the
connective tissue matrix precludes its critical participa-
tion in the complex process of gas exchange.
The nature and physiologic consequences of the
*Pulmonary Branch, National Heart, Lung, and Blood Institute,
Bldg. 10, Rm. 6DO6, Bethesda, MD 20205.
tPresent address: Pulmonary Division, Ohio State University
Hospital, Columbus, OH 43210.
pulmonary lesion resulting from proteolytic injury
reflect the specificity of certain proteases for the
structural macromolecules comprising the extracellular
matrix ofthe alveolar structures. In fact, both collagen-
ase and elastase, classes ofproteases whose substrates
includethe principal structuralelements oflungconnec-
tive tissue, have been implicated in several diffuse,
chronic lung diseases (4-6). In this context, we will
consider: (1) the components ofnormal lung connective
tissue; (2) the proteases relevant to their disruption in
diffuse lung disease; (3) the modulation of protease
activity within the alveolar structures; and (4) connec-
tive tissue proteases and antiproteases in human lung
disease.
Connective Tissue Matrix of the
Human Alveolar Structures
The major components ofthe lung's connective tissue
include collagen, elastic fibers, proteoglyeans and other
glycoproteins (1,7). Ofthese matrix proteins, collagen is
the most prevalent, comprising 6 to 20% of lung dry
weight (8).GADEK ET AL.
Collagen
Collagen is found in the alveolar structures in at least
four different molecular forms. Among the pulmonary
connective tissue constituents, the molecular structure
of collagen is the best characterized. The collagen
molecule is a rodlike unit formed by three polypeptide
chains (a-chains) arranged in the form of a triple helix
(9). These triple helical molecules polymerize to form
collagen fibrils, the structures that ultimately account
forthe tensile strength ofcollagenous connective tissue.
An unusually repetitive primary structure of the
collagen a-chain plays a critical role in conferring a
unique helical structure to the collagen molecule. Along
the collagen a-chain, glycine, prolineandhydroxyproline
residues appear as triplet of gly-pro-X (where X is
commonly hydroxyproline), a structure that is repeated
frequently along the length of the polypeptide chain
(9,10). Although the precise nature of the interchain
interactions that produce the unique triple helix of the
collagen molecule have not been completely delineated,
it is known that the relative position and frequency of
each of these amino acids, particularly glycine and
hydroxyproline, play an important role in the formation
of the helix. In addition to this common triplet repeat,
the at-chains also contain lysine and hydroxylysine,
residues that are involved in formation of covalent
crosslinks that permit the assembly of collagen mole-
cules into fibrils (9,10).
The principal differences among the collagen types
are the amino acid sequence within the polypeptide
chains and the types of polypeptide chains comprising
the triple helical molecule. Differences in the level of
hydroxylation of proline and lysine residues, glyco-
sylation ofthe lysine residues, the presence ofdisulfide
crosslinks and frequency of covalent crosslinks account
for the distinct macromolecular arrangement ofeach of
these collegen types and result in a variable capacity of
the different collagens to form fibrils.
Type I collagen, composed of two a1 (I)-chains and
one a2 (I)-chain, is the most abundant collagen type
present in the alveolar structures (1,8,10). Type I
collagen is distributed diffusely within the alveolar
interstitium but is not present in the endothelial or
epithelial basement membranes.
Type III collagen comprises three identical a1 (III)
polypeptide chains. Like Type I, it is an interstitial
collagen and partially corresponds to "reticulin" demon-
strable by light microscopy.
Type IV collagen is the major collagen type compris-
ing epithelial and endothelial basement membranes in
the lung; it is not found in the interstitial matrix (10).
Type IV collagen is composed of at least two distinct
polypeptides [a1(IV), a2 (IV)], but it is not clear
whether these chains combine to form the Type IV
molecule, orwhetherthe different chains segregate into
separate Type IV collagens composed of homogeneous
a-chains (9).
Type V collagen is also present in the alveolar
structures but its exact location is controversial. While
some investigators assign it solely to the basement
membrane, others find it throughout the interstitium
(9-11). In general, it is considered to be a "pericellular"
collagen that forms a surface matrix around cells such
as smooth muscle cells. Type V collagen is composed of
three chains [a1 (V), a2 (V), a3 (V)], but like Type IV
collagen, the exact chain distribution within each Type
V molecule is controversial (9,10).
In the human alveolar structures, the ratio ofType I
and Type III collagenis approximately 3:1 (8). Together,
Type I plus Type III comprise 90 to 95% of the total
collagen, with Type IV and Type V making up the
remainder. The contribution ofeach collagen type to the
structure and function of the alveolar interstitium is
incompletely understood. By virtue of its tensile
strength, abundance, distribution, and ability to form
fibers up to 200 nm in diameter, Type I likely plays a
dominant role, determining alveolar shape and distensi-
bility (1,10). In addition, Type I collagen contributes to
the cellular organization of the interstitium by serving
as a site of attachment for fibroblasts through another
matrix glycoprotein, fibronectin (see below) (11). The
role of Type III is less clear, but it also serves as an
anchor for fibronectin-mediated cell attachment. The
mechanical properties of Type III are not known, but
there is evidence that it may modulate Type I fiber
formation (10). Type IV collagen likely modulates
basement membrane structure and mechanical proper-
ties (11). Although not yet studied with lung cells, it is
known that Type IV can serve as an attachment site for
epithelial cells (12) through laminin, another basement
membrane consituent (see below). The role of Type V
collagen in lung structure and function is unknown.
There is some recent evidence that it may play a role in
fixing basement membranes to the underlying stroma
(9-11).
Elastic Fibers
Elastic fibers are composed of at least two com-
ponents, elastin and microfibrils. Elastin is composed of
large, extremely insoluble polymers of crosslinked,
identical protein subunits called tropoelastin (1,10). The
tropoelastin polypeptide has a molecular weight of
approximately 70,000 daltons and containslarge propor-
tions of nonpolar amino acids such as leucine, proline
and valine. Like collagen, elastin also contains hydroxy-
proline residues; however, these are infrequent and
represent only 1% of tropoelastin's amino acids (com-
pared to 10% for collagen) (10). Unlike other connective
tissue components present in the alveolar structures,
elastin contains no carbohydrate side chains (13). The
tropoelastin units of elastin are linked together by
covalent bonds through the lysine residues. While two
of these crosslink units, desmosine and isodesmosine,
are unique to elastin, a third, the lysinonorleucine
crosslink, is also present in collagen (10). Current
information suggests that the tropoelastin monomer is
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similar throughout the lung; there is little evidence of
elastin polymorphism (14). While there is a relative
paucity ofinformation regarding the microfibrillar com-
ponent of elastic fibers, it is distinct from elastin by
virtue of the prevalence of polar, acidic amino acids,
and the presence of cysteine and carbohydrate side
chains (13).
Light microscopic evaluation suggests that elastic
fibers make up a branching fiber network throughout
the interstitium of the alveolar structures (15). At the
ultrastructural level, elastic fibers appear either cylin-
drical or as fenestrated sheets. The elastin component
appears as an amorphous material that forms the core
of the elastic fiber while the microfibillar component
forms cylinders or cables 10 to 12 nm in diameter (16).
In the mature lung, elastic fibers are found in close
proximity to collagen fibers and proteoglyeans (17).
Elastic fibers have rubberlike properties, an attribute
that undoubtedly plays a major role in modulating
elastic recoil during the respiratory cycle. In this
context, destruction of elastic fibers is central to the
pathogenesis of lung disorders associated with loss of
elastic recoil (2,3).
Proteoglycans
The proteoglycans are the principal constituents of
the so-called "ground substance" of the alveolar struc-
tures. These macromolecules are organized into a
central protein core from which extend a number of
carbohydrate side chains. Ofthe proteoglyean molecule,
10 to 30% is polypeptide in nature and the remainder
carbohydrate (10). The carbohydrate side chains are
repeating disaccharide subunits called glycosamino-
glycans; in the alveolar interstitium they include hyalu-
ronic acid, chondroitin-4-sulfate, chondroitin-6-sulfate,
dermatan sulfate, heparin, and heparin sulfate (10,17).
The proteoglycans are distributed throughout the inter-
stitium; by analogy to other tissues it is likely that
proteoglycans are also present in basement membranes.
The contribution of proteoglyeans to the mechanical
properties ofthe lungis unknown. However, by virtue of
their ability to retain water, proteoglycans may signifi-
cantly influence function. They may also contribute to
lung structure by maintaining the proper spatial rela-
tionships between other extracellular components and
cells.
Other Glycoproteins
Fibronectin, a major cell surface glycoprotein, is
present in the stroma and basement membranes of the
alveolar structures. Fibronectin mediates cell-matrix
(and possibly cell-cell) interactions by virtue of its
ability to bind to some collagens (particularly lypes I
and III), and some glycosaminoglycans (9,10,18).
Laminin is a large glycoprotein present in basement
membranes. It polymerizes into large aggregates and
interacts with other connective tissue components,
notably Type IV collagen (18). As such, laminin is
thought to anchor epithelial and endothelial cells to
Irype IV collagen.
Connective Tissue Proteases of
Potential Relevance to Chronic
Inflammatory Diseases of the
Alveolar Structures
It is logical to expect that the proteases with poten-
tial relevance to the pathogenesis of lung disease are
those whose substrates include the major structual
connective tissue proteins (Table 1).
Collagenase
Given the critical contribution of collagen to the
structure of the normal lung, the presence of enzyme
Table 1. Connective tissue proteases of potential relevance to chronic inflammatory diseases of the alveolar structures.
Elastic fibers
Presence Form Collagen type Other glycoproteins
Cellular in normal when Microfibrillar
Protease source lung released I III IV V Elastin component Proteoglycans Fibronectin Laminin
Collagenase Alveolar Yes Latent Yesa Yesa Yesb No ? No No No
macrophage
Fibroblast Yes Latent Yes Yesa No ? No No No
Neutrophil No Active Yesa No No ? No No No
Eosinophil No ? Yesa Yesa No ? No No No
Elastase Alveolar Yes Active ? ? ? Yes ? ? ? ?
macrophage
Neutrophil No Active Noc Yesd No Yes ? Yes Yes ?
Cathepsin G Neutrophil No Active Noc No No ? Yese ?
a Site of attack at or near classic collagenase sensitive site 3/4 of the length of the molecule from the N-terminus ofType I and Type III
collagen (20).
b Cultured macrophages produce a metallo proteinase that degrades Type V collagen (35).
c Attacks N- and C-terminal nonhelical ends (telopeptides) of the collagen molecule, but does not degrade Trype I helex (37).
d Site of cleavage is in a region of the triple helix of Type III that is less tightly coiled (32,41).
e Cleavage of native elastin occurs at a rate 10-fold less rapid than neutrophil elastase (45).
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within the alveolar structures capable of cleaving the
collagen molecule would be expected to have a profound
effect on structure and function ofthe lung. Mammalian
collagenases are unique amongproteases in their ability
to cleave helical Type I collagen at neutral pH (19). The
classical human collagenases are metalloproteases; i.e.,
they require the presence ofdivalent cations in order to
express their activity. Furthermore, collagenases are
commonly secreted in a latent form, necessitating
partial proteolysis for the generation of the active
enzyme (20).
The action of a classical collagenase is distinguished
by a remarkable degree ofsubstrate specificity. Among
all the structural proteins of the lung, the action of
human collagenases is restricted to native, triple-helical
collagen (19,20). Cleavage of Type I collagen by this
class ofproteases typically occurs at the leu-gly peptide
bond approximately three-quarters ofthe length ofeach
component a-chain from its amino terminal end. This
proteolysis cleaves the Type I molecule into two pieces,
an N-terminal piece that represents three-quarters of
the molecule and a C-terminal piece that represents the
remaining one-quarter. Because neither piece can main-
tain a stable triple helical conformation at body
temperature, they denature, leavingthe cleaved compo-
nent a-chains which are then vulnerable to attack by
nonspecific proteases (21,22).
The alveolar macrophage (23), lung fibroblast (24),
neutrophil (25) and eosinophil (26) are potential cellular
sources of collagenase within the lower respiratory
tract of man. With the notable exception of the
neutrophil, collagenase release from these cells appears
to depend upon de novo protein synthesis of the
enzyme. In contrast, the bulk of the neutrophil's
collagenase activity exists in a preformed state that is
stored after synthesis (27). Recent studies have demon-
strated that the neutrophil collagenase is contained in
the "specific" (secondary) lysosomal granules of the
neutrophil and is readily released into the extracellular
milieu in response to a variety of phagocytic and
inflammatory stimuli (28).
For the alveolar macrophage (23,24), the fibroblast
(25) and possibly the eosinophil (26), collagenase is
releasedinaninactiveform. Themechanismsthatcontrol
activation in vivo are not clear; in most cases, however,
it is likely modulated by otherneutral proteases (29). At
least for the rabbit, the alveolar macrophage releases a
latent collagenase as well as a nonspecific neutral
protease capable of activating the collagenase (29).
The mechanisms regulating the release ofcollagenase
by the fibroblast and eosinophil are unclear. For the
neutrophil, most inflammatory stimuli (e.g., phago-
cytosis, immune complexes) result in rapid collagenase
release. The same is true foralveolarmacrophages from
experimental animals (23). For human alveolar macro-
phages, however, collagenase release appears to be
constitutive i.e., unaffected by stimulation (24).
Not only does collagenase demonstrate specificity for
the general class ofmacromolecules termed "collagens,"
but certain collagenases are specific for certain collagen
types. Alveolar macrophage, fibroblast and eosinophil
collagenases are examples of classic collagenases: they
degrade collagen Types I and III. In contrast, neutro-
phil collagenase readily attacks Tylpe I but not Type III
(27,30).
In the normal alveolar structures, the only known
sources ofcollagenase are the alveolar macrophage and
the fibroblast (31). Presumably, these collagenases are
responsible for the turnover ofinterstitial collagen that
continually occurs inthe normal lowerrespiratory tract.
Inanumberofchronicinflammatorydisorders, however,
neutrophils and/or eosinophils are also present, sig-
nificantly adding to the collagenase burden (32). Fur-
thermore, many of these disorders are also character-
ized by increased numbers of alveolar macrophages
and/or fibroblasts in the alveolar structures, further
increasing the potential sources of collagenases.
Elastase
In contrast to the collagenases, the elastases are
neutral proteases that attack all ofthe connective tissue
structural proteins of the alveolar structures (33-36)
(Table 1). Their designation as "elastases" derives from
their ability to cleave the peptide bonds of the native,
insoluble elastin molecule (37). However, at least one
prototype ofthis class, neutrophil elastase, is capable of
degrading collagen (32,34,35) elastic fibers (37), the
protein portion of proteoglycans (36) and fibronectin
(33).
Studies of alveolar macrophage and neutrophil elas-
tases have demonstrated that while both are capable of
cleaving elastin, they are different enzymes (23,24). For
example, while the elastase ofthe human neutrophil has
a serine-dependent active site and does not require free
divalent cations for its elastolytic activity (like human
and porcine pancreatic elastase) (38), the human alveo-
lar macrophage releases an elastolytic enzyme that is
inhibited by metal chelating agents (24). This suggests
that, like the murine peritoneal macrophage, the human
alveolarmacrophage elastaseisametalloproteaserather
than a serine protease (23,24). Furthermore, as in the
case of collagenases, there are potentially important
differences in the packagingand amounts ofelastaselike
enzymes produced by the human alveolar macrophage
and the neutrophil. The alveolar macrophage releases
only small quantities ofits elastase under conditions of
cell culture and requires de novo protein synthesis to do
so (24). Like the regulation of collagenase release, the
human alveolar macrophage releases elastase in a
constitutive fashion (24). In contrast, the neutrophil
carries large amounts of its serine elastase in a pre-
formed state and rapidly releases this elastase in
response to inflammatory stimuli (2). Neutrophil elas-
tase is consigned to the primary (i.e., azurophilic)
lysosomal granules (27).
Since the alveolar macrophage is the only known
source ofelastase in the normal lowerrespiratory tract,
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it is presumed that its elastase accounts for turnover of
elastin that normally takes place in the alveolar
structures. In some chronic inflammatory disorders,
however, there are two potential sources: the increased
number of alveolar macrophages and neutrophils (31).
Interestingly, recent studies by Campbell et al. have
demonstrated that human alveolar macrophages have a
surface receptor that recognizes neutrophil elastase
(39). This is likely mediated by mannose receptors, a
general class of receptors on the macrophage surface
that recognizes carbohydrate residues on neutrophil
elastase (40).
Other Proteases
In addition to collagenase and elastase, there are
undoubtedly other proteases capable of destroying at
least some ofthe proteins that make up the connective
tissueframeworkofthealveolarstructures. Forexample,
pepsin can attack the telopeptides of collagens Type I
and III, trypsin attacks Type III collagen near the
"collagenase" site (41), cathepsin B attacks the protein
portion of proteoglycans (42,43), trypsin destroys
fibronectin (18,44) and thrombin cleaves laminin (45).
The relevance ofsuch proteases to chronic inflammatory
disease of the lower respiratory tract is unknown.
However, the alveolar macrophage does release at least
one nonspecific neutral protease (29) and the neutrophil
carries cathepsin G (a nonspecific neutral protease that
can also attack elastin, albeit at a very slow rate) in its
primary granules (46). Such enzymes likely play a role
in disorders ofthe alveolar structures, buttheirrelative
importance and substrate targets inthese situations are
not completely understood (2).
Modulation of Protease Activity
within the Alveolar Structures
In view of the susceptibility of the connective tissue
framework of the lung to the action of collagenase and
elastase, it is apparent that the normal structure-
function characteristics of the lung must be dependent
on homeostatic mecnanisms that serve to minimize the
access ofthese proteases to the protein skeleton ofthe
lung. This function is subserved by: (1)reg,ulation ofthe
influx of prntease producing cells to the lung paren-
chyma and (2) antiproteases, a cla3s of proteins that
modulate protease activity by forming intermolecular
complexes with proteases.
Regulation of the Influx of Protease
Producing Cells
The extent of protease activity within the alveolar
structures depends, to a large extent, on the burden of
protease producing cells present. Beyond that present
in the normal lung, the presence of protease producing
cells in the lower respiratory tract depends on the
status of the mechanisms capable of modulating the
directed migration (i.e., chemotaxis) (47) of inflam-
matory cells from the circulating blood pool into the
lungparenchyma. The chemotaxis ofinflammatory cells
from blood to lung depends upon chemotactic factors
within the alveolar structures and chemotactic factor
inhibitors that modulate the action of the chemotactic
factors (21).
The chemotactic factors mostrelevanttothe collagen-
ase and elastase burden of the lung are those that
attract neutrophils. In chronic lung disorders, most
neutrophils are attracted by a chemotactic factor re-
leased by alveolar macrophages (48). Following a var-
iety of stimuli, the macrophage releases at least two
chemotactic factors that attract neutrophils, a low
molecular weight lipid and a protein (48,49). In acute
inflammatory disorders where there is significant tran-
sudation of plasma into the alveolar structures, C5a, a
fragment ofthe C5 component ofcomplement undoubt-
edly also plays a role in attracting neutrophils (50).
Modulation of chemotactic factor activity is provided
bycirculatinginhibitors ofchemotactic factors (so called
"chemotactic factor inhibitor") as well as inhibitors of
chemotaxis directed at the inflammatory cell itself
(cell-directed inhibitors) (47). Through this system of
regulatory proteins, the influx of protease-bearing
inflammatory cells (primarily, thecirculatingneutrophil)
can be checked, preventing excessive infiltration of the
alveolar structures with neutrophils and their pre-
formed proteases (2).
The collagenase and elastase burden of the lower
respiratory tract may also be increased by expanding
the numbers of alveolar macrophages in the alveolar
structures. While more selective for neutrophils, both
the macrophage derived chemotactic factor and C5a
also attract monocytes (51), the cellular precursor of
alveolar macrophages (52). In addition, fragments of
elastin attract monocytes (22,53), providing a mecha-
nism that expands macrophage numbers in those cases
where elastase is allowed to work unimpeded on lung
elastin, resulting in elastin fragments.
In normal lung, neutrophils are rarely found (31),
suggesting that either few chemotactic factors are
presentand/orchemotactic factorinhibitors areprevent-
ing those chemotactic factors present from operating.
Consistent with this concept are the findings that: (1)
alveolar macrophages from normal individuals are not
spontaneously releasing the neutrophil chemotactic fac-
tor (48); and (2) no active elastase or collagenase can be
detected in epithelial fluid obtained from the lower
respiratory tract of normal individuals (31).
Antiproteases of the Alveolar Structures
In those instances when chemotactic activity over-
rides the chemotactic inhibitory mechanisms, and
inflammatory cells such as polymophonuclear leuko-
cytes are permitted to enter the alveolar structures, a
second line ofdefense forthe connective tissue elements
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is provided by the antiproteases present within the
extracellular milieu of the lung (Table 2). Given the
critical contribution of elastin and collagen to the
structural and functional characteristics of the normal
lung, the antiproteases most relevant to the integrity of
lung structure are those that inhibit the action of
collagenase and elastase (2).
There are two elastases ofpotential importance to the
alveolar structures: neutrophil elastase and alveolar
macrophage elastase.
There are three physiologic inhibitors of neutrophil
elastase that have been considered as possible antielas-
tases of the lower respiratory tract, including: otl-anti-
trypsin, a2-macroglobulin, and the so-called "bronchial
mucus inhibitor" (22). However, direct assessment of
the antineutrophil elastase protection of the human
alveolarstructures has shownthat, byfar, a1-antitrypsin
is the major antineutrophil elastase (22). Although it is
a serumproteinproduced byhepatocytes, ox1-antitrypsin
has a molecular weight (52,000 daltons) that permits
ready diffusion through the lower respiratory tract. In
fact, a1-antitrypsin is found in the same concentration
in lung (relative to albumin) as in serum, and aol-anti-
trypsin provides greater than 95% of the functional
antineutrophil elastase protection to the alveolar struc-
tures (22). In contrast, a2-macroglobulin, another se-
rum antiprotease, is mostly excluded from the human
alveolar structures as a result of its large molecular
weight (725,000 daltons) (22,54). While resident alveo-
lar macrophages can be shown to produce a2-macro-
globulin in cell culture (55), locally produced a2-macro-
globulin likely makes little contribution to the total
antineutrophil elastase activity ofthe lower respiratory
tract. In fact, the ratio of oxl-antitrypsin to at2-macro-
globulin recoverable from the alveolar structures is
approximately 50:1 on a weight basis and greater than
200:1 on a molar basis (2,22). Importantly, although it
is the principal antineutrophil elastase of the upper
respiratory tract, the bronchial mucus inhibitor does not
appear to be produced or distributed at the alveolar
level (22).
The concept that a1-antitrypsin is the major anti-
neutrophil elastase of the lower respiratory tract has
been confirmed by studies performed in patients with
serum oal-antitrypsin deficiency. The lower respiratory
tract of these individuals is virtually devoid of func-
tional antineutrophil elastase activity, strongly arguing
against a significant role for a2-macroglobulin and the
bronchial mucus inhibitor in contributing significantly
to the antineutrophil elastase screen of the lower
respiratory tract (2,22).
The physiologic inhibitory profile ofthe human alveo-
lar structures for human alveolar macrophage elastase
is not well defined. Unlike neutrophil elastase, the
alveolarmacrophage elastase is not inhibited by a1-anti-
trypsin, the principal antineutrophil elastase of the
human lower respiratory tract. In addition, there is
disagreement regarding resistance ofmacrophage elas-
tase to ac2-macroglobulin, the antiprotease with the
broadest inhibitory profile (7). However, in view of the
paucity of elastaselike activity produced by the human
alveolar macrophage and the fact that human macro-
phage release of elastase does not appear to be aug-
mented by inflammatory stimuli, the relevance of this
macrophage protease and its inhibitory profile to human
lung disease remains to be clarified.
While the human alveolar structures appear to have
ample antielastase protection, current evidence sug-
gests that it is relatively devoid of anticollagenases.
Evaluation of normal individuals by bronchoalveolar
lavage has demonstrated that there is significantly less
functional anticollagenase activity within the human
lower respiratory tract than antineutrophil elastase
activity (56). This finding implies that when both
Table 2. Antiproteases of potential relevance of protease-antiprotease balance within the human alveolar structures.
Protease inhibition profile Present in Present in
Alveolar macrophage ~~~~~~~~lower upper Alveolar macrophage Neutrophil Molecular respiratory respiratory
Antiprotease Source Collagenase Elastase Collagenase elastase Cathepsin G weight tract tract
a1-Antitrypsin Serum 0 0 0 Yes 52,000 (51 + 11 ,pg)a Yesb
(liver)
cx2-Macroglobulin Serum (liver), Yesc Yesc Yes +d Yes 725,000 (2 + 0.4 ,pg)a Yesb
lung
fibroblasts
Bronchial mucus Bronchial 0 ? 0 Yes Yes 11,000 (< 1)a Yesb
inhibitory epithelium
13l-Anti- Serum ? 0 + 0 0 50,000 Probably ?
collagenasee
al-Anti- Serum ? ? 0 0 Yes 42,000 ? ?
chymotrypsin
a Quantification of antiproteases in the normal lower respiratory tract is expressed as micrograms of antiprotease/mg albumin in
order to correct for the variable dilution during bronchoalveolar lavage (22).
b Data of Gadek et al. (22).
c Data of Gadek et al. (24).
d In the presence of equivalent amounts of cxl-antitrypsin and Qt2-macroglobulin, neutrophil elastase binds to al-antitrypsin exclusively
until the protease binding sites of al-antitrypsin are saturated, i.e., a2-macroglobulin is a "second-line" inhibitor of neutrophil elastase 21.
e Data of Wooley et al. (58).CONNECTIVE TISSUE PROTEASES
collagenase and elastase are released within the alveo-
lar structures, there is a greater opportunity for the
expression of uninhibited collagenase activity, i.e., the
specificity ofproteolytic assault on the connective tissue
of lung may be regulated by the quantity of specific
antiprotease available at the inflammatory focus within
the lung parenchyma.
The precise nature of the anticollagenase activity of
the lower respiratory tract is unknown. Although early
studies suggested a1-antitrypsin could inhibit neutro-
phil collagenase, it is now recognized that this is not the
case (56-58). As yet, no anticollagenases have been
identified that are selective for the collagenase of any
one celltype relevant tolunginflammation; i.e., alveolar
macrophage, neutrophil, or eosinophil collagenases.
The principal physiologic anticollagenases relevant to
preservation of lung collagen are likely those found in
normal human serum, i.e., a2-macroglobulin and 1l-
anticollagenase (57,58). As noted earlier, U2-macro-
globulin in excluded from the lower respiratory tract as
a result ofits prohibitively large molecular size (22). In
contrast, based on its molecular weight of 50,000
daltons, 13l-anticollagenase should have access to the
alveolar structures. However, the serum concentration
of ,l-anticollagenase is only 30 to 50 mg/dL (57),
approximately one-fifth that ofac-antitrypsin. Although
it has not been measured directly, a similar ratio of
13l-anticollagenase and al-antitrypsin within the lower
respiratory tract would account for the observed differ-
ences between anticollagenase and antielastase activity
at this site.
The chymotrypsinlike protease of the neutrophil,
cathepsin G, is a protease whose role in lung disease
remains to be defined. This protease has not been
identified within the lungs ofpatients with any chronic
lung disease. In contrast to the other two neutral
proteases of the neutrophil, collagenase and elastase,
cathepsin G has no specific connective tissue substrate
to attack in the lung (Table 1). While it has been shown
that cathepsin G is capable ofdegrading lung elastin, it
does so at a rate that is 10-fold slower than equimolar
amounts of neutrophil elastase (45). However, it is of
interest that oxygen radical generation by the neutro-
phil is dependent on the presence ofa chymotrypsinlike
protease associated with the cell membrane (59). The
identity of this chymotrypsinlike neutrophil protease
and the question of its relationship to cathepsin G
remains to be clarified. Nevertheless, this evidence
provides a mechanism through which a neutrophil
protease may participate in oxidant mediated lung cell
injury as well as proteolytic injury of the extracellular
matrix.
Since cathepsin G is presently an uncertain candidate
for participation in lung disease, it is understandable
that the source and amount ofanticathepsin G activity
in the normal human lower respiratory tract has not
been the subject of extensive study to date. Although
human serum contains a potent inhibitor ofcathepsin G
inthe form ofa1-antichymotrypsin (42), direct measure-
ment ofthis serum antiprotease inhuman lowerrespira-
tory tract fluid has not been done.
Connective Tissue Proteases
and Antiproteases in Human
Lung Disease
Current concepts of the role of proteolysis in human
lungdisease derive from the theory that maintenance of
normal alveolar structure is dependent on the existence
ofa homeostatic balance between the connective tissue-
specific proteases, i.e., elastase and collagenase, and
the antiproteases that inhibit these proteases. In this
scheme, disease results from an imbalance between the
connective tissue proteases and the antiproteases such
that expression of connective tissue proteolysis is per-
mitted (2). Theoretically, this can occur in two ways:
either from an excess of protease or from a relative
deficiency of antiprotease. A strong case can be con-
structedfortherelevanceofthis"protease-antiprotease"
theory to the pathogenetic mechanisms operative in two
major classes of chronic lung disease: destructive lung
disease (i.e., emphysema) and the interstitial (fibrotic)
lung diseases.
Destructive Lung Disease
The earliest evidence suggesting a role for antipro-
teases in the pathogenesis of destructive lung disease
was derived from the studies of Laurell and Eriksson
(60). While studying serum protein electrophoretic
patterns in large numbers ofindividuals, these investi-
gators noted that, in rare individuals, the o1-globulin
band was missing. Remarkably, they found that all of
these individuals also had early onset destructive lung
disease (60). It is now recognized that the missing
protein wasoxl-antitrypsin, the majorantielastase ofthe
alveolar structures.
The earliest direct evidence suggesting a role for
proteases in destructive lung disease came from the
studies ofGross et al. (61). By the instillation ofpapain
(a protease with a broad spectrum of activity) into the
lungs ofexperimental animals, these workers were able
to produce a lesion which had remarkable similarity to
that of human emphysema, i.e., it caused diffuse
destruction ofalveolar septal walls (61). Takingthe lead
from these studies, other investigators subsequently
demonstrated that the severity ofthe destructive lesion
correlated with the relative elastolytic activity of the
instilled protease i.e., the relative ability ofthe enzyme
to destroy elastin (62). Furthermore, the production of
emphysema by the instillation of human neutrophil
elastase into experimental animals provides compelling
evidence of the potential role of this enzyme in human
destructive lung disease (5,6). As will be discussed
below, there is now clear evidence that active elastase
and collagenase can be found in the lungs of at least
some individuals with destructive lung disease (63).
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Theoretically, the maximum opportunity for the ex-
pression offree elastase activity within the emphysema-
tous lung would occur in a clinical setting in which both
the elastase burden is increased and the antielastase
screen in reduced. Indeed, recent studies have shown
that individuals with a1-antitrypsin deficiency have
both mechanisms contributing to the pathogenesis of
their destructive lung disease (63).
The otl-antitrypsin-deficient patient has lessthan 10%
ofthe normal functional antielastase activity within the
lower respiratory tract (22). Formerly it was presumed
that these individuals developed destructive lung dis-
ease as a result of the "normal" quantity of neutrophil
elastase present within the lung. However, it now
appears that there is an influx of neutrophils into the
alveolar structures of the a1-antitrypsin-deficient pa-
tient who develops destructive lungdisease. The mecha-
nism by which neutrophils are attracted to the lungs of
these patients is unclear, but it is known that their
alveolar macrophages are spontaneously producing a
chemotactic factor for neutrophils and that they have a
deficiency of a serum chemotactic factor inhibitor (64).
Regardless of the mechanism, the neutrophil influx in
the a1-antitrypsin-deficient lung represents increased
elastase activity in concert with deficient antielastase
protection, i.e., the optimal situation for demonstration
of active elastase within the emphysematous lung. In
fact, analysis offluid recovered from the lower respira-
tory tract of the majority of cx1-antitrypsin-deficient
patients demonstrates the presence ofactive neutrophil
elastase (63). Furthermore, these individuals also have
active neutrophil collagenase within the alveolar struc-
tures (63). Thus, it is probable that in the case of this
form of destructive lung disease, all the connective
tissue components of the connective tissue network of
the alveolar structures are degraded (2).
Recently, several studies have served to demonstrate
the potentially important parallels that exist between
the inherited form of destructive lung disease (i.e.,
a1-antitrypsin-deficiency) and the acquired form of
emphysema (i.e., cigarette smoking). Current evidence
now suggests that exposure to cigarette smoke ad-
versely affects both sides of the protease-antiprotease
balance normally protecting the human lung i.e., the
antiprotease activity is reduced and protease activity
increased in the lung as a result ofcigarette smoking. It
is known that the oxidative products of cigarette
combustion reduce the capacity of a1-antitrypsin to
inhibit elastase invitro and in the lungs ofexperimental
animals (65,66). In addition, evaluation of the a1-
antitrypsin recovered from the lungs ofindividuals who
smoke cigarettes has shown that, although present in
normal amounts, the lung ac-antitrypsin of smokers
retains only approximately 60% of its elastase inhibi-
tory activity (67). In addition, Hunninghake et al. have
shown that the lungs of these individuals contain a
significant numberofneutrophils (68). Thistwo-pronged
assault on the elastase-antielastase balance of the
alveolar structures provides a means by which cigarette
smoking results in proteolytic injury to the human lung
similar to that which occurs in the genetic form of
destructive lung disease, a.1-antitrypsin-deficiency (2).
Interstitial Lung Disease
Theprinciplesofprotease-antiproteasebalanceopera-
tive in destructive lung disease appear to have applica-
tion to certain aspects ofthe pathogenesis ofthe chronic
interstitial diseases. In idiopathic pulmonary fibrosis
(IPF), a prototype ofthe interstitial lung diseases, the
presence ofactive collagenase within the lower respira-
tory tract of affected individuals is associated, with
marked abnormalities oflungstructure and function (4).
Typically, the alveolar structures of these patients are
distorted by derangement ofnormal collagen structure;
there is fragmentation and fraying ofthe collagen fibers
as well as deposition of collagen in a disorderly array
(69). It is likely that disruption of the collagen fibers
apparent at the electron microscopic level reflects
specific proteolytic attack by an active collagenase. In
this context, bronchoalveolar lavage analyses of these
patients have demonstrated that they have an active
collagenase in their lower respiratory tract (4).
There are several cell types that may represent the
source of the active collagenase present in the lower
respiratory tract ofpatients with idiopathic pulmonary
fibrosis. In addition to the alveolar macrophage, it is
known that the lung fibroblast produces collagenase as
does the neutrophil and eosinophil (inflammatory cells
that are both present in the alveolar structures ofthese
individuals). However, recent studies of the collagen
substrate profiles ofthe collagenase produced by each of
these cell types, when matched with the profile of the
enzyme recovered from the IPF lung, strongly suggest
that the neutrophil is the source of this collagenolytic
activity (70).
Evaluation ofthe antielastase screen ofthe IPF lung
demonstrates that it is close to normal i.e., adequate
antielastase protection is provided by a1-antitrypsin,
but there is very little anticollagenase protection (70).
In this context, it becomes apparent why IPF, cigarette
smoking and atl-antitrypsin-deficiency are all associated
with neutrophils in the alveolar structures, yet IPF is a
fibrotic (i.e., collagen derangement) disease, while
cigarette smoking and a1-antitrypsin-deficiency are de-
structive disorders. The most tenable hypothesis to
explain the net expression of active neutrophil prote-
ases in the fibrotic and destructive diseases is that the
specific form of the disease reflects the modulating
effect of specific lung antiproteases. In support of this
premise, it has been shown that the IPF lung is devoid
of functional anticollagenase (70), yet contains nearly
75%ofthenormalantielastaseactivity(67). Incontrast,
the a1-antitrypsin-deficient lung is devoid of both
anticollagenase and antielastase, and the cigarette
smoker's lung has little anticollagenase and 40 to 50%
normal antielastase (2). Therefore, the net effect of
neutrophil accumulation and protease release in the
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IPF lung is the persistant action ofneutrophil collagen-
ase and the absence of active neutrophil elastase (i.e.,
the elastase is bound irreversibly by aol-antitrypsin).
Conversely, the accumulation of neutrophils in the
a.1-antitrypsin deficient lung and in the cigarette smo-
kers' lung results in the continuous expression of both
collagenase and elastase since these individuals possess
insufficient amounts of both protease inhibitors. Thus,
it is probable that the specificity ofthe pulmonary lesion
in these two prototypes ofchronic diffuse lungdisease is
a reflection of the local balance between neutrophil
connective tissue proteases and their physiologic inhib-
itors.
Continued study ofthe quantity and specificity ofthe
connective tissue proteases and antiproteases of the
alveolar structures and the factors that serve to main-
tain the balance necessary to preserve normal lung
structure should further the understanding of the
pathogenetic mechanisms operative in chronic lung
diseases. Importantly, an understanding of these bio-
logic mechanisms offers the opportunity forthe develop-
ment of specific therapy in these chronic disorders.
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